FDA
-
-
-
-
-
-
-
RedHill explores opaganib for ebola outbreak response
-
-
-
-
-
-
-
Joint U.S. Commercialization of RedHill's Talicia® Commences
-
-
-
-
-
-
-
RedHill Biopharma secures final $10.5 million court judgment
-
-
-
-
-
-
-
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
-
-
-
-
-
-
-
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
RedHill Biopharma (RDHL) Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
-
-
-
-
-
-
-
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
-
324,250 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

